noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

City of Iowa City, IA

Remember to clear sidewalks after second snowstorm of the week
North Dakota Farmers Union

Matt Perdue Elected President of NDFU
City of Worcester, MA

Applications Open for Public Facilities Projects via Community[...]

Healthcare

Nikon Corporation

04/15/2025 | Press release | Distributed by Public on 04/15/2025 00:03

Nikon CeLL Innovation Enters into a Strategic License Agreement with RoosterBio, a US Company, to Enable GCTP/GMP Manufacturing Platform of Human Mesenchymal Stem Cells and[...]

TOKYO - Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBio), a leading stem cell technology company in the US.

This agreement provides the Japanese biopharma industry with an end-to-end solution for development and manufacturing of human mesenchymal stem cells (MSC) and extracellular vesicle (EV) therapeutics. Drug developers can leverage RoosterBio's technology platform to accelerate the development of their advanced therapies with NCLi, and then seamlessly transition to clinical manufacturing within NCLi's GCTP^*1/GMP^*2 facility designed specifically for cell therapies.

Through this collaboration, NCLi's capabilities include cell expansion, harvest, formulation, and cryopreservation of MSC in 2D flasks and 3D bioreactor^*3, as well as downstream processing for EV purification and drug product manufacturing. RoosterBio and NCLi have successfully completed 2D flasks and 3D bioreactor MSC and EV technology transfer activities at clinically relevant manufacturing scales.

*1GCTP: An abbreviation of Good Gene, Cellular, and Tissue-based Products Manufacturing Practice. Statement of conformity based on Ministerial Ordinance regarding manufacturing management and quality control for regenerative medicine products.
*2GMP: An abbreviation of Good Manufacturing Practice. Statement of conformity based on Ministerial Ordinance regarding pharmaceutical products and quasi-drugs.
*3bioreactor: A device that uses microorganisms and enzymes to synthesize and decompose substances. It is now used for large scale cell culture for Regenerative medicine.

RoosterBio accelerates human mesenchymal stem/stromal cell (MSC) and extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. RoosterBio is driven by clients' success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale.

Nikon Corporation published this content on April 15, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 15, 2025 at 06:03 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]